The global albinism drug market is emerging as a specialized yet steadily growing segment within the rare disease therapeutics industry. The market encompasses treatments for conditions such as oculocutaneous albinism, X-linked ocular albinism, Hermansky-Pudlak syndrome, and Chediak-Higashi syndrome, with a focus on both drug-based therapies and supportive care solutions. Market Drivers and...